Log in
NASDAQ:LPCN

Lipocine Stock Forecast, Price & News

$1.59
-0.04 (-2.45 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.56
Now: $1.59
$1.65
50-Day Range
$1.20
MA: $1.41
$1.63
52-Week Range
$0.30
Now: $1.59
$2.39
Volume1.54 million shs
Average Volume2.15 million shs
Market Capitalization$104.44 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Read More
Lipocine logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383
Employees12

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$170,000.00
Book Value$0.25 per share

Profitability

Net Income$-13,010,000.00

Miscellaneous

Market Cap$104.44 million
Next Earnings Date3/12/2021 (Estimated)
OptionableOptionable
$1.59
-0.04 (-2.45 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lipocine (NASDAQ:LPCN) Frequently Asked Questions

How has Lipocine's stock been impacted by Coronavirus (COVID-19)?

Lipocine's stock was trading at $0.4511 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LPCN shares have increased by 252.5% and is now trading at $1.59.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Lipocine?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Lipocine
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Lipocine?

Wall Street analysts have given Lipocine a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lipocine wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Lipocine's next earnings date?

Lipocine is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Lipocine
.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) released its quarterly earnings data on Tuesday, November, 10th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01.
View Lipocine's earnings history
.

What price target have analysts set for LPCN?

1 Wall Street analysts have issued 12 month price objectives for Lipocine's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Lipocine's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price.
View analysts' price targets for Lipocine
.

Who are some of Lipocine's key competitors?

What other stocks do shareholders of Lipocine own?

Who are Lipocine's key executives?

Lipocine's management team includes the following people:
  • Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 63, Pay $471.44k)
  • Mr. Morgan R. Brown CPA, M.B.A., CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 52, Pay $349.2k)
  • Logan Morse, VP of Sales, Marketing & Operations (Age 50)
  • Dr. Anthony DelConte M.D., M. D., Chief Medical Director (Age 62)

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Who are Lipocine's major shareholders?

Lipocine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.45%) and GSA Capital Partners LLP (0.12%). Company insiders that own Lipocine stock include John W Higuchi, Mahesh V Patel and Morgan R Brown.
View institutional ownership trends for Lipocine
.

Which institutional investors are buying Lipocine stock?

LPCN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., and GSA Capital Partners LLP. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi, and Mahesh V Patel.
View insider buying and selling activity for Lipocine
.

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $1.59.

How big of a company is Lipocine?

Lipocine has a market capitalization of $104.44 million and generates $170,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,010,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Lipocine employs 12 workers across the globe.

What is Lipocine's official website?

The official website for Lipocine is www.lipocine.com.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.